2LI Zhengyu1, ZHAO Xia1, YANG Jinliang2 & WEI Yuquan2 1. Department of Gynecology and Obstetrics, West China Second Hospital of Sichuan University, Chengdu 610041, China,2. National Key Laboratory of Biotherapy of Human Diseases, West China Hospital of Sichuan University, Chengdu 610041, China.Proteomics profile changes in cisplatin-treated human ovarian cancer cell strain[J].Science China(Life Sciences),2005,48(6):648-657. 被引量：3
1Alban A,David SO,Bjorkesten L,et al.A novel experimental design for comparative two-dimensional gel analysis:two-dimensional difference gel electrophoresis incorporating a pooled internal standard[J].Proteomics,2003,3(1):36-44.
2Tonge R,Shaw J,Middleton B,et al.Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology[J].Proteomics,2001,1(3):377-396.
3Urbani A.A proteomic investigation into etoposide chemo-resistance of neuroblastoma cell lines[J].Proteomics,2005,5(3):796-804.
4Liotta LA, Ferrari M, Petricoin E. Clinical proteomics: written in blood. Nature 2003; 425: 905.
5Rai AJ, Chan DW. Cancer proteomics: Serum diagnostics for tumor marker discovery. Ann N Y Acad Sci 2004; 1022: 286-94.
6Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: Drawing attention to potential problems. J Natl Cancer Inst 2004; 96: 353-6.
7Ransohoff DF. Lessons from controversy: ovarian cancer screening and serum proteomics. J Natl Cancer Inst 2005; 97: 315-9.
8Colantonio DA, Chan DW. The clinical application of proteomics. Clin Chim Acta 2005; 357: 151-8.
9Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004; 3:367-78
10Aebersold R. Mann M, Mass spectrometry-based proteomics. Nature 2003; 422: 198-207.
1Koti M, Gooding R J, Nuin P, et al. Identification of the IGF1/PI3K/NF KB/ERK gene signalling networks associ- ated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer [ J ]. BMC Cancer,2013,13:549.
2Ozdemir F, Altinisik J, Karateke A, et al. Methylation of tumor suppressor genes in ovarian cancer [ J ]. Exp Ther Med,2012,4(6) :1 092- 1 096.
3Doherty JA, Rossing MA, Cushing-Haugen KL, et al. ESR1/ SYNE1 polymorphism and invasive epithelial ovarian cancer risk :an Ovarian Cancer Association Consortium study [ J ]. Cancer Epidemiol Biomarkers Prey,2010,19 ( 1 ) :245 - 250.
4Terry KL, Tworoger SS, Gates MA, et al. Common genetic variation in IGF1, IGFBP1 and IGFBP3 and ovarian cancer risk[ J]. Carcinogenesis,2009,30(12) :2 042 - 2 046.
5Januchowski R, Zawierucha P, Rucinski M, et al. Extracel- lular matrix proteins expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line [ J ]. Biomed Res Int,2014,2014:365 -867.
6Ma Y, Ma L, Guo Q, et al. Expression of bone morphogenet- ic protein-2 and its receptors in epithelial ovarian cancer and their influence on the prognosis of ovarian cancer pa- tients[J]. J Exp Clinical Can Res,2010,29:85.
7Anglesio MS, George J, Kulbe H, et al. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis in- hibitor sunitinib in ovarian clear cell cancer [ J ]. Clin Can Res,2011,17(8) :2 538 -2 548.
8Orchel J, Witek L, Kimsa M, et al. Expression patterns of kinin-dependent genes in endometrial cancer[ J ]. Int J Gy- necol Cancer,2012,22(6) :937 -944.
9Duerr EM, Mizukami Y, Ng A, ct al. Defining molecular classifications and targets in neuro- endocrine tumors through DNA mieroarray analysis [ J ]. En- docr Relat Cancer,2008,15 ( 1 ) :243 - 256.
10Samimi G, Manorek G, Castel R, et al. cDNA microarray- based identification of genes and pathways associated with oxaliplatin resistance [ J ]. Cancer Chemother Pharmacol, 2005,55(1) :1 -11.
